-
One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester.
Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH.
BJOG 2000;107:1271-5. -
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta -hCG and PAPP-A at 10-14 weeks of gestation.
Tul N, Spencer K, Noble P, Chan C, Nicolaides K.
Prenat Diagn 1999;19:1035-42. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7. -
Maternal serum inhibin-A and free beta-hCG concentrations in trisomy 21 pregnancies at 10-14 weeks of gestation.
Noble PL, Wallace EM, Snijders RJ, Groome NP, Nicolaides KH.
BJOG 1997;104:367-71. -
Early prenatal diagnosis of triploidy.
Jauniaux E, Brown R, Snijders RJ, Noble P, Nicolaides KH.
Am J Obstet Gynecol 1997;176:550-4. -
Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
Noble PL, Abraha HD, Snijders RJ, Sherwood R, Nicolaides KH.
Ultrasound Obstet Gynecol 1995;6:390-5. -
Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.
Brizot ML, Snijders RJ, Butler J, Bersinger NA, Nicolaides KH.
Br J Obstet Gynaecol 1995;102:127-32.